Managing the Adverse Effects of Nonsteroidal Anti-inflammatory Drugs

Paola Patrignani; Stefania Tacconelli; Annalisa Bruno; Carlos Sostres; Angel Lanas

Disclosures

Expert Rev Clin Pharmacol. 2011;4(5):605-621. 

In This Article

Five-year View

The challenge of the next few years will be to learn how to use drugs at the individual level. This will lead to the development of a personalized medicine of NSAIDs. In order to realize this objective, it will be necessary to develop genetic and biochemical markers which might be useful to identify the responders to NSAIDs or who are uniquely susceptible at developing thrombotic or GI events by COX inhibition. This will lead to the development of individual responder approaches. In this context, the use of pharmacogenomics tools together with pharmacoepidemiological methods will open the way to a new era of pharmacovigilance. This will allow to put information out on drug hazard as quickly as possible and to make appropriate decision on risk management. However, the road is still very long and it is necessary for more work to be performed before this knowledge can be applied to daily practice.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....